PE20080061A1 - Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 - Google Patents
Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3Info
- Publication number
- PE20080061A1 PE20080061A1 PE2007000515A PE2007000515A PE20080061A1 PE 20080061 A1 PE20080061 A1 PE 20080061A1 PE 2007000515 A PE2007000515 A PE 2007000515A PE 2007000515 A PE2007000515 A PE 2007000515A PE 20080061 A1 PE20080061 A1 PE 20080061A1
- Authority
- PE
- Peru
- Prior art keywords
- task
- alkyl
- amida
- inhibitors
- potassium channels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE AMIDA FORMULA (Ia) DONDE R(1) Y R(2) SON CADA UNO R(20)-CrH2r, DONDE R(20) ES H, CH3, CH2F, CF3, ENTRE OTROS; r ES DE 0 A 8; R(3), R(4), R(5) Y R(6) SON CADA UNO H, F, Cl, ALQUILO(C1-C5), CICLOALQUILO(C3-C8), ENTRE OTROS; R(7) ES H O ALQUILO(C1-C4); R(8) ES UN COMPUESTO DE FORMULA (II) O (III) DONDE R9 ES H, OR(28) U OCOR(28), EN DONDE R(28) ES H O ALQUILO(C1-C4); R(10) Y R(11) SON CADA UNO H O ALQUILO(C1-C4); R(12), R(13), R(14) Y R(15) SON CADA UNO H, F, CN, CF3, NO2, CICLOALQUILO(C3-C8), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(BUTIL-1-SULFONILAMINO)-N-[1(R)-(6-METOXIPIRIDIN-3-IL)PRO-PIL]BENZAMIDA, N-(2-PIRIDIN-3-ILETIL)-2'-{[2-(4-METOXIFENIL)ACETILAMINO]-METIL}BIFENIL-2-CARBOXAMIDA, N-(2,4-DIFLUOROBENCIL)-3-(2-{[2-(4-METOXIFENIL)ACETILAMINO]-METIL}FENIL)TIOFENO-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LOS CANALES DE POTASIO TASK-1 Y TASK-3 SIENDO UTILES EN EL TRATAMIENTO DE RONQUIDO, SINDROME DE RESISTENCIA DE LAS VIAS SUPERIORES, APNEAS DEL SUENO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006019589A DE102006019589A1 (de) | 2006-04-27 | 2006-04-27 | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
DE102006049527A DE102006049527A1 (de) | 2006-10-20 | 2006-10-20 | Inhibitoren des TASK-1 und TASK-3 Ionenkanals |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080061A1 true PE20080061A1 (es) | 2008-03-24 |
Family
ID=38258824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000515A PE20080061A1 (es) | 2006-04-27 | 2007-04-25 | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 |
Country Status (27)
Country | Link |
---|---|
US (1) | US20090149496A1 (es) |
EP (1) | EP2012758A2 (es) |
JP (1) | JP5161871B2 (es) |
KR (1) | KR101390239B1 (es) |
CN (1) | CN101636154B (es) |
AR (1) | AR060822A1 (es) |
AU (1) | AU2007245891B2 (es) |
BR (1) | BRPI0710946A2 (es) |
CA (1) | CA2650391C (es) |
CO (1) | CO6140023A2 (es) |
CR (1) | CR10342A (es) |
DO (1) | DOP2007000083A (es) |
EC (1) | ECSP088847A (es) |
GT (1) | GT200800213A (es) |
HK (1) | HK1138183A1 (es) |
IL (1) | IL194868A (es) |
MA (1) | MA30357B1 (es) |
MX (1) | MX2008012920A (es) |
NO (1) | NO20084513L (es) |
NZ (1) | NZ572231A (es) |
PE (1) | PE20080061A1 (es) |
RU (1) | RU2436577C2 (es) |
SG (1) | SG163543A1 (es) |
TN (1) | TNSN08431A1 (es) |
TW (1) | TWI398432B (es) |
UY (1) | UY30313A1 (es) |
WO (1) | WO2007124849A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105130957A (zh) * | 2009-05-29 | 2015-12-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
SG175703A1 (en) * | 2009-06-03 | 2011-12-29 | Sanofi Aventis Deutschland | Crystalline phases of 2'-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide |
US8664425B2 (en) * | 2010-02-02 | 2014-03-04 | Honeywell International Inc. | Bluegreen fluorescent compounds |
WO2011103715A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
EA023648B1 (ru) * | 2011-09-12 | 2016-06-30 | Санофи | ИНДАНИЛЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ |
JP5893143B2 (ja) * | 2011-09-12 | 2016-03-23 | サノフイ | インダニル置換の4,5,6,7−テトラヒドロ−1H−ピラゾロ[4,3−c]ピリジン、医薬としてのその使用、及びそれらを含む医薬製剤 |
BR112014006180A2 (pt) | 2011-09-16 | 2017-04-11 | Sanofi Sa | 4, 5, 6, 7-tetraidro-1h-pirazol [4, 3-c] piridinas substituídas, seu uso como medicamento e preparações farmacêuticas que compreendem as mesmas |
AU2011376721B2 (en) | 2011-09-16 | 2017-06-08 | Sanofi | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
BR112014018767B1 (pt) * | 2012-02-03 | 2022-03-03 | Sanofi | Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende |
CN104721832A (zh) * | 2013-12-18 | 2015-06-24 | 深圳先进技术研究院 | 携带编码光敏感离子通道蛋白基因的表达载体在制备调控呼吸节律药物中的应用 |
WO2016149621A1 (en) * | 2015-03-18 | 2016-09-22 | The Johns Hopkins University | Novel monoclonal antibody inhibitors targeting potassium channel kcnk9 |
TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
JOP20190005A1 (ar) * | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
CN110325110B (zh) | 2016-11-10 | 2022-08-09 | 纽约州立大学研究基金会 | 用于气道阻塞的系统、方法和生物标记 |
WO2018119126A1 (en) * | 2016-12-20 | 2018-06-28 | The University Of Chicago | L-pag derivatives for treatment of sleep disordered breathing (sdb) |
EP3338764A1 (de) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
EP3338803A1 (de) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
JOP20190148A1 (ar) * | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
JOP20190141A1 (ar) * | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
US11073429B2 (en) | 2018-09-24 | 2021-07-27 | Rosemount Inc. | Non-invasive process fluid temperature indication for high temperature applications |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
DE19929076A1 (de) * | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
US6531495B1 (en) * | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
WO2002017897A2 (en) * | 2000-08-30 | 2002-03-07 | Primecyte, Inc. | Methods for treating tumors using sulfonyl compounds |
GB2372503A (en) * | 2000-10-19 | 2002-08-28 | Glaxo Group Ltd | Voltage-gated potassium channel polypeptides |
DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10060807A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10061876A1 (de) * | 2000-12-12 | 2002-06-20 | Aventis Pharma Gmbh | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10121002A1 (de) * | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
US7781457B2 (en) * | 2003-09-23 | 2010-08-24 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
DE102004009931A1 (de) * | 2004-02-26 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
BRPI0516915A (pt) * | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
DE102005028845A1 (de) * | 2005-06-22 | 2006-12-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
-
2007
- 2007-04-13 BR BRPI0710946-6A patent/BRPI0710946A2/pt not_active IP Right Cessation
- 2007-04-13 SG SG201004686-0A patent/SG163543A1/en unknown
- 2007-04-13 MX MX2008012920A patent/MX2008012920A/es active IP Right Grant
- 2007-04-13 WO PCT/EP2007/003293 patent/WO2007124849A2/en active Application Filing
- 2007-04-13 CN CN2007800146321A patent/CN101636154B/zh not_active Expired - Fee Related
- 2007-04-13 JP JP2009506946A patent/JP5161871B2/ja not_active Expired - Fee Related
- 2007-04-13 RU RU2008146755/15A patent/RU2436577C2/ru not_active IP Right Cessation
- 2007-04-13 EP EP07724232A patent/EP2012758A2/en not_active Withdrawn
- 2007-04-13 AU AU2007245891A patent/AU2007245891B2/en not_active Ceased
- 2007-04-13 CA CA2650391A patent/CA2650391C/en not_active Expired - Fee Related
- 2007-04-13 KR KR1020087026167A patent/KR101390239B1/ko not_active IP Right Cessation
- 2007-04-13 NZ NZ572231A patent/NZ572231A/en not_active IP Right Cessation
- 2007-04-25 PE PE2007000515A patent/PE20080061A1/es not_active Application Discontinuation
- 2007-04-25 DO DO2007000083A patent/DOP2007000083A/es unknown
- 2007-04-25 TW TW096114514A patent/TWI398432B/zh not_active IP Right Cessation
- 2007-04-25 AR ARP070101797A patent/AR060822A1/es unknown
- 2007-04-27 UY UY30313A patent/UY30313A1/es unknown
-
2008
- 2008-10-06 CR CR10342A patent/CR10342A/es unknown
- 2008-10-10 GT GT200800213A patent/GT200800213A/es unknown
- 2008-10-15 CO CO08109803A patent/CO6140023A2/es unknown
- 2008-10-16 US US12/252,516 patent/US20090149496A1/en not_active Abandoned
- 2008-10-23 IL IL194868A patent/IL194868A/en not_active IP Right Cessation
- 2008-10-24 MA MA31332A patent/MA30357B1/fr unknown
- 2008-10-24 EC EC2008008847A patent/ECSP088847A/es unknown
- 2008-10-24 TN TNP2008000431A patent/TNSN08431A1/en unknown
- 2008-10-27 NO NO20084513A patent/NO20084513L/no not_active Application Discontinuation
-
2010
- 2010-04-07 HK HK10103417.7A patent/HK1138183A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
PE20090641A1 (es) | Amidas heterociclicas | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20120136A1 (es) | Compuestos derivados de n-acilsulfonamidas como inhibidores de bcl-2 | |
PE20081385A1 (es) | Derivados de nicotinamida | |
PE20121354A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
PE20121385A1 (es) | DERIVADOS DE SULFONAMIDA COMO AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CANCER Y ENFERMEDADES INMUNES | |
AR072490A1 (es) | 1,2,5- oxadiazoles como inhibidores de indolamina 2,3 dioxigenasa | |
PE20091096A1 (es) | Compuestos organicos | |
PE20090727A1 (es) | DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7 | |
PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
BRPI0507506A (pt) | compostos | |
EA201070619A1 (ru) | Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений | |
PE20070528A1 (es) | Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1 | |
PE20090694A1 (es) | Compuestos moduladores de sirtuinas | |
AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
PE20091400A1 (es) | Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac | |
PE20121496A1 (es) | Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes | |
CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
EA201071019A1 (ru) | Кристаллические формы производных фениламинопиримидина | |
AR062299A1 (es) | Derivados de bencimidazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |